1. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2.
- Author
-
Focosi D, Franchini M, Casadevall A, and Maggi F
- Subjects
- Humans, Antiviral Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, COVID-19 immunology, Antibodies, Viral therapeutic use, Antibodies, Viral immunology, Clinical Trials as Topic, Antibodies, Neutralizing therapeutic use, Antibodies, Neutralizing immunology, SARS-CoV-2 immunology, SARS-CoV-2 drug effects, Spike Glycoprotein, Coronavirus immunology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal immunology, COVID-19 Drug Treatment
- Abstract
Background: Anti-spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure., Objectives: We review here the current pipeline of anti-spike mAb's, discussing in detail the most promising candidates., Sources: We scanned PubMed, ClinicalTrials.gov and manufacturers' press releases for clinical studies on anti-spike monoclonal antibodies., Content: We present state-of-art data clinical progress for AstraZeneca's AZD3152, Invivyd's VYD222, Regeneron's REGN-17092 and Aerium Therapeutics' AER-800., Implications: The anti-spike monoclonal antibody clinical pipeline is currently limited to few agents (most being single antibodies) with unknown efficacy against the dominant JN.1 sublineage. The field of antibody-based therapies requires boosting by both manufacturers and institutions., (Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF